I believe life is precious. Even more so for cancer patients. If they can have a fighting chance against cancer while at the same time having a better quality of life like enjoying quality time with family and friends, this is a rare combination.
if a pharma entity wants to win the China license or the Japan license and wants to get it against less competition they will move early, before the P3 results. I would not be surprised if a China licensing deal is in place prior to results.
Agreed that this is entirely plausible. Mesoblast, an Australian biotech developing stem cell treatments just entered into a partnership deal with Tasly Pharmaceuticals of China. This was done even before the completion of their ongoing phase 3 trial in the US. They also have a similar partnership with JCR in Japan. I believe this is just one of many examples which the Chinese are pursuing.